Loading...
OTCM
PXMVF
Market cap2mUSD
Aug 30, Last price  
0.03USD
Name

Pixium Vision SA

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
-11.61%
Revenues
Net income
CFO

Profile

Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat bilndness, which replace the normal physiological function of the eye's photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the visual information to the brain via the optic nerve. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.
IPO date
Jun 19, 2014
Employees
42
Domiciled in
FR
Incorporated in
FR

Valuation

No data to show